Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Published Date: 31 Dec 2024

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

improvements in the treatment of prostate cancer resistant to chemotherapy.

2.

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.

3.

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

4.

The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.

5.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot